Treated-group

Control group

Total

Erythema

6 weeks

No

61 (52.9%)

14 (43.8%)

75

Mild

38 (36.9%)

11 (34.4%)

49

Intense

4 (3.9%)

7 (21.9%)

11

12 weeks

No

56 (73.7%)

16 (50.0%)

72

Mild

15 (19.7%)

9 (28.1%)

24

Intense

5 (6.6%)

7 (21.9%)

12

Dischromia

6 weeks

No

29 (28.2%)

10 (31.3%)

39

Mild

67 (65.2%)

18 (56.3%)

85

Intense

7 (6.8%)

4 (12.5%)

11

12 weeks

No

48 (63.2%)

7 (21.9%)

55

Mild

24 (31.6%)

22 (68.8%)

46

Intense

4 (5.3%)

3 (9.4%)

7

Atrophy

6 weeks

No

83 (80.6%)

23 (71.9%)

106

Mild

18 (17.5%)

7 (21.9%)

25

Notorious

2 (1.9%)

2 (6.3%)

4

12 weeks

No

65 (85.5%)

20 (62.5%)

85

Mild

9 (11.8%)

9 (28.1%)

18

Notorious

2 (2.6%)

3 (9.4%)

5

Hypertrophy

6 weeks

No

83 (80.6%)

26 (81.2%)

109

Mild

14 (13.6%)

4 (12.5%)

18

Intense

6 (5.8%)

2 (6.2%)

8

12 weeks

No

67 (89.3%)

25 (78.1%)

72

Mild

7 (9.4%)

6 (18.8%)

24

Intense

1 (1.3%)

1 (3.1%)

12